Aravive Inc(ARAV) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Aravive, Inc., a clinical-stage biopharmaceutical company, develops treatments for life-threatening diseases. Its lead product candidate is AVB-500, a decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase Ib/II clinical trial for the treatment of platinum- resistant recurrent ovarian cancer, as well as for the treatment of clear cell renal cell carcinoma, triple negative breast cancer, acute myeloid leukemia, and pancreatic cancer. The company has a strategic collaboration agreement with WuXi Biologics to develop novel high-affinity bispecific antibodies targeting cancer and fibrosis. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is headquartered in Houston, Texas.

Current Price

$4.84

RSI

26.561

Beta:

3.167126

March 16, 2021
2.1M
4.2M

6.516 %
-5.009 %

$5,685,000
$4,753,000
$1,371,000
$40,000,000
$0
$0
19.609 %
246.681 %
-2817.578 %
100.000 %
0.000 %

$-30,543,000
$-18,218,000
$-76,333,000
$-85,226,000
$-95,570,000
$-82,177,000
-40.353 %
318.998 %
11.650 %
12.137 %
-14.014 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.